AZA-ESA combo: a new standard for higher risk MDS?
Moshe
M
Mittelman
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D001374:Azacitidine / Q000008:administration & dosage*; D005260:Female; D006397:Hematinics / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000401:mortality*
D000964:Antimetabolites, Antineoplastic; D006397:Hematinics; D001374:Azacitidine